MyFinsight
Home
Blog
About
Proceeds from the
issuance of common...
$54,030K
(14.96%↑ Y/Y)
Payments of costs related
to public offering
-$340K
(-200.00%↓ Y/Y)
Net cash provided by
financing activities
$53,529K
(9.46%↑ Y/Y)
Canceled cashflow
$531K
Net increase
(decrease) in cash, cash...
$31,364K
(554.22%↑ Y/Y)
Canceled cashflow
$22,165K
Proceeds from the
issuance of common...
-$357K
Payments of finance lease
principal
$174K
(-87.69%↓ Y/Y)
Change in fair value of
derivatives
-$5,155K
(-136.35%↓ Y/Y)
Change in fair value of
contingent earnout...
$2,718K
(106.14%↑ Y/Y)
Stock-based compensation
expense
$2,608K
(-45.91%↓ Y/Y)
Inventory
-$2,266K
(-120.66%↓ Y/Y)
Depreciation expense
$1,337K
(-49.45%↓ Y/Y)
Accrued expenses
$688K
(128.63%↑ Y/Y)
Inventory reserve
$669K
Amortization expense
$449K
(-57.12%↓ Y/Y)
Amortization of debt discount
$298K
Non-cash interest
expense
$225K
(-94.85%↓ Y/Y)
Accounts receivable
-$104K
(-148.60%↓ Y/Y)
Net cash used in
operating activities
-$22,061K
(59.90%↑ Y/Y)
Net cash used in
investing activities
-$104K
(86.93%↑ Y/Y)
Canceled cashflow
$16,517K
Net (loss) income
-$36,802K
(-2584.94%↓ Y/Y)
Purchase of property and
equipment
$104K
(-86.93%↓ Y/Y)
Accounts payable
-$912K
(-142.48%↓ Y/Y)
Prepaid expenses and
other current assets
$864K
(271.09%↑ Y/Y)
Back
Back
Cash Flow
Humacyte, Inc. (HUMAW)
Humacyte, Inc. (HUMAW)
source: myfinsight.com